Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01615068 · ClinicalTrials.gov registry record
An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 1,007
- Enrollment target
NCT01615068 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 1,007 participants.
The verdict
NCT01615068 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 1,007 participants
- Enrollment target
Study Summary
This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic therapy; patients may be enrolled up to 6 months after the diagnosis. Data will be collected for up to 8 years.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,007 participants |
| Start Date | 2012-06-05 |
| Est. Completion | 2017-11-16 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01615068
The ClinicalTrials.gov registry entry for NCT01615068 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,007 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01615068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01615068 about?
NCT01615068 is a clinical study titled "An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)". This multi-center, prospective observational study will evaluate the treatment patterns, and the safety in patients with HER2-positive (HER2+) metastatic breast cancer (MBC). Eligible patients will have an initial metastatic breast cancer diagnosis that has not been previously treated with systemic ...
What is the current status of trial NCT01615068?
This trial is currently completed. The enrollment target is 1,007 participants. The study started on 2012-06-05. Estimated completion is 2017-11-16.
Who is sponsoring clinical trial NCT01615068?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.